Celiac Plexus Block to Treat Refractory Feed Induced Dystonia in Children with Severe Neurodisability: A Single

David I Campbell1, Rosalind M Rabone1, Ala Fadilah1

  • 1From the Sheffield Children's Hospital NHS Foundation Trust UK, Sheffield, United Kingdom.

JPGN Reports
|May 19, 2023
PubMed

Insights

Celiac plexus blockade (CPB) offers a safe and effective treatment for children with severe neurodisability experiencing feed intolerance or feed-induced dystonia (FID) when other therapies fail.

Area of Science:

  • Pediatric Gastroenterology
  • Interventional Radiology
  • Pain Management

Background:

  • Children with severe neurodisability often suffer from refractory feed intolerance, pain, or dystonia.
  • The neuroenteric system is significantly impacted by feeding issues in this population.
  • Existing therapies may be insufficient for managing these complex conditions.

Purpose of the Study:

  • To describe the procedure, safety, and outcomes of celiac plexus blockade (CPB) in children with neurodisability and feeding problems.
  • To evaluate CPB as a treatment for feed-induced dystonia (FID) and refractory feed intolerance.
  • To review the pathophysiological response to feeding in neurodisabled children.

Main Methods:

  • A 2-stage CT-guided temporary celiac plexus blockade followed by neurolysis technique was employed.
  • A case series of 5 pediatric patients with life-limiting conditions and significant disability was compiled.
  • The study involved 10 separate procedures in the 5 children.

Main Results:

  • Celiac plexus blockade (CPB) demonstrated positive outcomes in 3 out of 4 cases of pediatric feed-induced dystonia (FID).
  • Two of three patients on parenteral nutrition showed improved feed tolerance post-procedure.
  • All pediatric patients tolerated the procedure well, with no documented post-procedure complications.

Conclusions:

  • Celiac plexus blockade (CPB) is a safe treatment option for selected pediatric cases.
  • CPB can effectively manage life-threatening feed-induced dystonia or intestinal failure when other treatments have failed.
  • This interventional technique offers a viable solution for refractory feeding issues in neurodisabled children.

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
525
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
713
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
353
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
470
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
212
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.7K